Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295837217> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W4295837217 endingPage "S1249" @default.
- W4295837217 startingPage "S1248" @default.
- W4295837217 abstract "Berzosertib is a potent, first-in-class selective inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein kinase. Berzosertib is well tolerated and synergises with topotecan (TOP) in patients with advanced solid tumours." @default.
- W4295837217 created "2022-09-15" @default.
- W4295837217 creator A5006025076 @default.
- W4295837217 creator A5007777916 @default.
- W4295837217 creator A5009053310 @default.
- W4295837217 creator A5014006140 @default.
- W4295837217 creator A5015607597 @default.
- W4295837217 creator A5016893894 @default.
- W4295837217 creator A5045867102 @default.
- W4295837217 creator A5053917991 @default.
- W4295837217 creator A5054758172 @default.
- W4295837217 creator A5059741013 @default.
- W4295837217 creator A5084530609 @default.
- W4295837217 date "2022-09-01" @default.
- W4295837217 modified "2023-09-28" @default.
- W4295837217 title "1534P Phase II study of berzosertib + topotecan in patients with relapsed platinum (Pt)-resistant SCLC (DDRiver SCLC 250): Japanese safety run-in" @default.
- W4295837217 doi "https://doi.org/10.1016/j.annonc.2022.07.1629" @default.
- W4295837217 hasPublicationYear "2022" @default.
- W4295837217 type Work @default.
- W4295837217 citedByCount "0" @default.
- W4295837217 crossrefType "journal-article" @default.
- W4295837217 hasAuthorship W4295837217A5006025076 @default.
- W4295837217 hasAuthorship W4295837217A5007777916 @default.
- W4295837217 hasAuthorship W4295837217A5009053310 @default.
- W4295837217 hasAuthorship W4295837217A5014006140 @default.
- W4295837217 hasAuthorship W4295837217A5015607597 @default.
- W4295837217 hasAuthorship W4295837217A5016893894 @default.
- W4295837217 hasAuthorship W4295837217A5045867102 @default.
- W4295837217 hasAuthorship W4295837217A5053917991 @default.
- W4295837217 hasAuthorship W4295837217A5054758172 @default.
- W4295837217 hasAuthorship W4295837217A5059741013 @default.
- W4295837217 hasAuthorship W4295837217A5084530609 @default.
- W4295837217 hasBestOaLocation W42958372171 @default.
- W4295837217 hasConcept C126322002 @default.
- W4295837217 hasConcept C143998085 @default.
- W4295837217 hasConcept C161790260 @default.
- W4295837217 hasConcept C185592680 @default.
- W4295837217 hasConcept C2776694085 @default.
- W4295837217 hasConcept C2781209748 @default.
- W4295837217 hasConcept C518104683 @default.
- W4295837217 hasConcept C55493867 @default.
- W4295837217 hasConcept C71924100 @default.
- W4295837217 hasConceptScore W4295837217C126322002 @default.
- W4295837217 hasConceptScore W4295837217C143998085 @default.
- W4295837217 hasConceptScore W4295837217C161790260 @default.
- W4295837217 hasConceptScore W4295837217C185592680 @default.
- W4295837217 hasConceptScore W4295837217C2776694085 @default.
- W4295837217 hasConceptScore W4295837217C2781209748 @default.
- W4295837217 hasConceptScore W4295837217C518104683 @default.
- W4295837217 hasConceptScore W4295837217C55493867 @default.
- W4295837217 hasConceptScore W4295837217C71924100 @default.
- W4295837217 hasLocation W42958372171 @default.
- W4295837217 hasOpenAccess W4295837217 @default.
- W4295837217 hasPrimaryLocation W42958372171 @default.
- W4295837217 hasRelatedWork W1989997195 @default.
- W4295837217 hasRelatedWork W2033445808 @default.
- W4295837217 hasRelatedWork W2059153951 @default.
- W4295837217 hasRelatedWork W2061018452 @default.
- W4295837217 hasRelatedWork W2117976189 @default.
- W4295837217 hasRelatedWork W2124273755 @default.
- W4295837217 hasRelatedWork W2412406379 @default.
- W4295837217 hasRelatedWork W2466209479 @default.
- W4295837217 hasRelatedWork W2590783779 @default.
- W4295837217 hasRelatedWork W4244238644 @default.
- W4295837217 hasVolume "33" @default.
- W4295837217 isParatext "false" @default.
- W4295837217 isRetracted "false" @default.
- W4295837217 workType "article" @default.